- Raw materials
- Cephalosporins
- Cefotiam
Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Cefotiam API Manufacturers & Suppliers
6 verified results
All Cefotiam data. Full access. Full negotiation power
Commercial-scale Suppliers
All certificates
All certificates
All certificates
All certificates
All certificates
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Cefotiam | CAS No: 61622-34-2 | GMP-certified suppliers
A medication that treats severe bacterial infections across multiple systems by providing broad-spectrum antibacterial activity against susceptible pathogens.
Therapeutic categories
Primary indications
- For treatment of severe infections caused by susceptible bacteria
Product Snapshot
- Cefotiam is an injectable small molecule antibiotic available as a powder for solution
- It is primarily indicated for treating severe bacterial infections caused by susceptible strains
- The API is approved in certain markets and remains investigational in others
Clinical Overview
Clinically, cefotiam is indicated for the treatment of severe infections caused by susceptible bacterial strains. Its therapeutic use covers a range of systemic infections, including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections.
Pharmacodynamically, cefotiam exerts bactericidal effects by inhibiting bacterial cell wall synthesis. This occurs through binding to penicillin-binding proteins (PBPs), enzymes critical for the cross-linking of peptidoglycan chains in the bacterial cell wall. The disruption of cell wall biosynthesis compromises bacterial integrity, leading to cell lysis and death.
Key ADME characteristics include its distribution primarily in extracellular fluids, with renal elimination as the major excretion pathway. Cefotiam is known as a substrate and inhibitor of organic anion transporters OAT1 (SLC22A6) and OAT3 (SLC22A8), which influence its renal clearance. Such interactions may affect dosing considerations, particularly in patients with renal impairment.
Safety profiles note potential nephrotoxicity, warranting monitoring of renal function during therapy. Hypersensitivity reactions typical of beta-lactams may occur. Cefotiam's spectrum and safety profile require careful susceptibility testing and consideration of local resistance patterns.
Approved in multiple regions, cefotiam is utilized under various formulations globally. It is classified under beta-lactams, cephalosporins, and specifically as a second-generation cephalosporin in some regulatory contexts.
From an API sourcing perspective, strict adherence to current Good Manufacturing Practice (cGMP) and validation of chemical purity, especially regarding beta-lactam ring integrity, are critical. Suppliers should provide detailed spectral and chromatographic data to confirm identity and impurity profiles to ensure consistent excipient compatibility and clinical efficacy.
Identification & chemistry
| Generic name | Cefotiam |
|---|---|
| Molecule type | Small molecule |
| CAS | 61622-34-2 |
| UNII | 91W6Z2N718 |
| DrugBank ID | DB00229 |
Pharmacology
| Summary | Cefotiam is a third-generation cephalosporin antibiotic that exerts bactericidal effects by inhibiting bacterial cell wall synthesis through high affinity binding to penicillin-binding protein 1A. It demonstrates broad-spectrum activity against both Gram-positive and Gram-negative bacteria. Cefotiam is indicated for the treatment of severe infections caused by susceptible bacterial strains. |
|---|---|
| Mechanism of action | The bactericidal activity of cefotiam results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs). |
| Pharmacodynamics | Cefotiam is a third generation beta-lactam cephalosporin antibiotic that works by inhibiting bacterial cell wall biosynthesis. It is a broad spectrum antibiotic that is effective against Gram positive and Gram negative bacteria. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Penicillin-binding protein 1A | Clostridium perfringens (strain 13 / Type A) | inducer |
ADME / PK
| Absorption | Rapidly absorbed following intramuscular injection. Bioavailability is 60% following intramuscular injection. |
|---|---|
| Half-life | Approximately 1 hour. |
| Protein binding | 40% |
Formulation & handling
- Cefotiam is supplied as a powder for injection, indicating parenteral administration and requiring reconstitution prior to use.
- As a cephalosporin antibiotic with low logP and moderate water solubility, it is hydrophilic and may require aqueous formulation strategies.
- Stability considerations include protection from moisture and adherence to sterile handling conditions to maintain potency and prevent contamination.
Regulatory status
Supply Chain
| Supply chain summary | Cefotiam is primarily manufactured by Takeda Chemical Industries Ltd, indicating a limited number of originator companies involved in its production. The branded product has a presence in multiple regions, including the US, EU, and other markets. Patent expiries suggest existing or imminent generic competition, influencing the supply and sourcing dynamics within the API marketplace. |
|---|
Safety
| Toxicity | Adverse effects following overdosage include nausea, vomiting, epigastric distress, diarrhea, and convulsions. |
|---|
- Handle with care to avoid ingestion or inhalation, as overexposure may induce gastrointestinal distress and neurological symptoms
- Use appropriate personal protective equipment to prevent skin and eye contact due to potential irritant effects
- Ensure proper ventilation in handling areas to minimize risk of convulsions associated with accidental overdose exposure
Cefotiam is a type of Cephalosporins
Cephalosporins are a class of pharmaceutical active ingredients (APIs) widely used in the field of antibiotics. They belong to the beta-lactam family, which also includes penicillins. Cephalosporins are derived from a fungus called Acremonium cephalosporium and are known for their potent antimicrobial properties.
These APIs are commonly used to treat a wide range of bacterial infections, including respiratory tract infections, skin and soft tissue infections, urinary tract infections, and even meningitis. Cephalosporins work by inhibiting the synthesis of bacterial cell walls, leading to the disruption of bacterial growth and ultimately their destruction.
Cephalosporins are classified into generations based on their antimicrobial spectrum and activity against specific bacteria. The first-generation cephalosporins are effective against Gram-positive bacteria, while subsequent generations show broader activity against both Gram-positive and Gram-negative bacteria.
Pharmaceutical companies manufacture cephalosporins in various formulations, including tablets, capsules, injectable solutions, and suspensions. They are often prescribed by healthcare professionals and are available under different brand names in the market.
It is important to note that like other antibiotics, cephalosporins should be used judiciously to prevent the development of antibiotic resistance. Proper dosage and adherence to treatment guidelines are crucial to maximize their effectiveness and minimize the risk of resistance.
In conclusion, cephalosporins are a vital category of APIs widely used in the treatment of bacterial infections. Their broad spectrum of activity and effectiveness make them an essential tool in modern medicine.
Cefotiam API manufacturers & distributors
Compare qualified Cefotiam API suppliers worldwide. We currently have 6 companies offering Cefotiam API, with manufacturing taking place in 4 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| API Corp. | Producer | Japan | Japan | CoA, JDMF | 11 products |
| Daewoong Bio | Producer | South Korea | South Korea | CoA, JDMF | 12 products |
| Ehfield Co.,Ltd | Producer | China | China | CoA | 7 products |
| Hanmi Fine Chemical | Producer | South Korea | South Korea | CoA, JDMF | 18 products |
| Sandoz | Producer | Austria | Unknown | CoA, JDMF | 58 products |
| Yungjin Pharmaceutical | Producer | South Korea | South Korea | CoA, JDMF | 10 products |
When sending a request, specify which Cefotiam API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Cefotiam API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
